About Checkpoint Therapeutics
Checkpoint Therapeutics is a company based in New York (United States) founded in 2014 was acquired by Sun Pharma in March 2025. It operates as a HealthTech. Checkpoint Therapeutics has raised $58 million across 1 funding round from investors including Sun Pharma. The company has 24 employees as of December 31, 2022. Checkpoint Therapeutics offers products and services including UNLOXCYT™. Checkpoint Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter New York, United States
- Employees 24 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Checkpoint Therapeutics, Inc.
-
Annual Revenue
$41 K-60as on Dec 31, 2024
-
Net Profit
$-56.24 M-8as on Dec 31, 2024
-
EBITDA
$-56.17 M-8as on Dec 31, 2024
-
Total Equity Funding
$58 M (USD)
in 1 rounds
-
Latest Funding Round
$58 M (USD), Series C
Dec 21, 2015
- Investors
-
Employee Count
24
as on Dec 31, 2022
-
Acquired by
Sun Pharma
(Mar 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Checkpoint Therapeutics
Checkpoint Therapeutics offers a comprehensive portfolio of products and services, including UNLOXCYT™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
UNLOXCYT™ is developed as a therapeutic drug candidate.
Unlock access to complete
Funding Insights of Checkpoint Therapeutics
Checkpoint Therapeutics has successfully raised a total of $58M through 1 strategic funding round. The most recent funding activity was a Series C round of $58 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $58.0M
-
First Round
First Round
(21 Dec 2015)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2015 | Amount | Series C - Checkpoint Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Checkpoint Therapeutics
Checkpoint Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sun Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Checkpoint Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Checkpoint Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Checkpoint Therapeutics Comparisons
Competitors of Checkpoint Therapeutics
Checkpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Checkpoint Therapeutics
Frequently Asked Questions about Checkpoint Therapeutics
When was Checkpoint Therapeutics founded?
Checkpoint Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Checkpoint Therapeutics located?
Checkpoint Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Checkpoint Therapeutics a funded company?
Checkpoint Therapeutics is a funded company, having raised a total of $58M across 1 funding round to date. The company's 1st funding round was a Series C of $58M, raised on Dec 21, 2015.
How many employees does Checkpoint Therapeutics have?
As of Dec 31, 2022, the latest employee count at Checkpoint Therapeutics is 24.
What is the annual revenue of Checkpoint Therapeutics?
Annual revenue of Checkpoint Therapeutics is $41K as on Dec 31, 2024.
What does Checkpoint Therapeutics do?
Checkpoint Therapeutics, Inc. is engaged in the development of innovative therapeutic drug candidates, including UNLOXCYT. The company operates within the biotechnology sector, focusing on advancing various candidates through different stages of development. Their work is supported by publications and presentations that highlight research progress. Recently acquired by Sun Pharma, Checkpoint Therapeutics continues to contribute to healthcare solutions.
Who are the top competitors of Checkpoint Therapeutics?
Checkpoint Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
What products or services does Checkpoint Therapeutics offer?
Checkpoint Therapeutics offers UNLOXCYT™.
Who are Checkpoint Therapeutics's investors?
Checkpoint Therapeutics has 1 investor. Key investors include Sun Pharma.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.